ArticleJournal of translational medicine2026
EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease.
Anna Alvarez-Guaita et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.